Tonix Pharmaceuticals Completes Enrollment in Potentially NDA-Enabling Phase 3 RESILIENT Trial of TNX-102 SL for Management of Fibromyalgia
August 01, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Topline Data Expected Fourth Quarter 2023 Final Trial Required for Submission of a New Drug Application, if Successful CHATHAM, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals...
Tonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 ‘STROBE’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Binge-Eating Disorder
July 31, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Preliminary Data Show that Oxytocin Decreases Impulsivity and Reduces Food Intake TNX-1900 (Intranasal Potentiated Oxytocin) May Serve as a Novel Neuroendocrine Treatment for Binge-Eating Disorder ...
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites
July 28, 2023 08:00 ET
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company...
Tonix Pharmaceuticals Announces Pricing of $7 Million Public Offering
July 27, 2023 21:31 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., July 27, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced it has entered into a...
Tonix Pharmaceuticals Announces Proposed Public Offering
July 27, 2023 16:01 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., July 27, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced that it intends to offer...
Tonix Pharmaceuticals Announces Accelerating Completion of Enrollment in Phase 2 UPLIFT Study of TNX-601 ER (Racemic Tianeptine) for Major Depressive Disorder: Topline Data Now Expected in Fourth Quarter 2023
July 26, 2023 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
Reallocating Resources to Development of Single Isomer TNX-4300 (Estianeptine) Estianeptine in Preclinical Development Has Demonstrated Key Activities Related to in vivo Novel Object Recognition and...
[Latest] Global Mitral Valve Disease Market Size/Share Worth USD 6.1 Billion by 2032 at a 8.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
July 25, 2023 14:20 ET
|
Custom Market Insights
Austin, TX, USA, July 25, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Mitral Valve Disease Market Size, Trends and Insights By Treatment Type (Mitral...
Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement
July 24, 2023 07:30 ET
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage...
Tonix Pharmaceuticals Announces Data Supporting the Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, but not (R)-Tianeptine, in the In Vivo Rat Novel Object Recognition (NOR) Test
July 24, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
New Findings Support Development of Racemic Tianeptine and (S)-Tianeptine (Estianeptine) as First-in-Class Oral Therapies in Alzheimer’s Disease and Other Psychiatric and Neurodegenerative Conditions...
Biotech and Biopharma Executive Eliana Clark Joins Culture Biosciences’ Advisory Board
July 19, 2023 06:39 ET
|
Culture Biosciences
SAN FRANCISCO, July 19, 2023 (GLOBE NEWSWIRE) -- Culture Biosciences is excited to welcome Eliana Clark, PhD, Executive Vice President and Chief Technical Officer at Intellia Therapeutics, Inc., to...